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AbstrAct
Introduction The frequency of diabetes mellitus in 
childhood is increasing. Thus, more children and young 
people are at risk of developing diabetic retinopathy and 
diabetes related visual impairment. However, there is 
no consensus on optimal screening strategies for the 
paediatric population reflecting the lack of clarity about 
the current burden of disease in this group. We aim to 
estimate the prevalence of diabetic retinopathy in children 
and young people living with types 1 or 2 diabetes, and to 
investigate potential sources of heterogeneity in this figure 
so as to inform screening strategies for this population.
Methods and analysis PubMed and EMBASE will be 
searched from 1995 to 2016 using the OvidSP platform 
with no language restriction. Additionally, manual 
review of the references lists of included articles will be 
conducted. Two investigators will independently screen 
titles and abstracts for potential eligibility. Studies which 
report prevalence of diabetic retinopathy among general 
populations of children and young people with types 
1 or 2 diabetes will be included. Pooled prevalence 
estimates of diabetic retinopathy reported in studies 
with sample size greater than 200 participants will be 
calculated by the random effect model. Forest plots will 
be used to summarise individual and pooled estimates 
of the prevalence. Heterogeneity between studies will be 
assessed using the I2 statistic and explored through meta-
regressions and subgroup analyses if the necessary data 
are available.
Ethics and dissemination Ethics approval is not required 
as this is a review of anonymised published data. We 
will report the findings of this systematic review in a 
peer-reviewed journal, and share it with the relevant 
professionals including health authorities through our 
Diabetic Eye disease in Childhood Study collaborative 
network.
clinical trail registration PROSPERO 
(CRD42017067178).
bAckground
Diabetic retinopathy is the most common 
preventable cause of visual impairment in 
young adults.1 The rising prevalence of child-
hood type 1 and type 2 diabetes2–4 has led to 
a significant increase in the number of chil-
dren and young people at risk of visual loss.
Microvascular retinal damage is a marker 
of general vascular health, indicative of a 
need for greater diabetic disease control. The 
more advanced, but still asymptomatic, stages 
of diabetic retinopathy require additional 
ophthalmic intervention to reduce the risk of 
irreversible visual loss. Screening for diabetic 
retinopathy in children and young people is 
recommended by many national population 
health programmes, with commencement 
of annual retinal examination determined 
either by age (typically age 10–12 years) or 
duration of disease (typically 2–5 years from 
diagnosis).5–7
Although it has been suggested that 
these recommendations need to be revised 
based on recent evidence on the burden of 
the disease in this population, there is no 
consensus on the direction of these modifi-
cations.8–12 Variable estimates of the preva-
lence of diabetic retinopathy may be due in 
part to heterogeneity between study popula-
tions, diagnostic methods or definitions of 
diabetic retinopathy used in the studies.13 14 
Consensus about screening strategies for the 
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Protocol
strengths and limitations of this study
 ► This formal systematic review will provide currently 
unavailable information on the prevalence of diabetic 
retinopathy in the paediatric population.
 ► Only studies reporting diagnostic methods and 
grades of diabetic retinopathy will be included to 
enhance precision.
 ► To increase the applicability of the findings, two 
severity cut-offs will be used to calculate prevalence 
estimates.
 ► As with all systematic reviews, the poor reporting of 
methods in primary studies might compromise the 
exploration of the heterogeneity.
2 Ibanez-Bruron MC, et al. BMJ Open 2017;7:e018578. doi:10.1136/bmjopen-2017-018578
Open Access 
Table 1 Search strategy MEDLINE (OvidSP)
Category # Keyword
Children and young people 1. exp Child/
2. exp Adolescent/
3. exp Pediatrics/
4. child*.mp.
5. teen*.mp.
6. school age.mp.
7. 1/OR 6
Diabetes 8. exp Diabetes Mellitus, Type 1/
9. exp Diabetes Mellitus, Type 2/
10. exp Diabetes Complications/
11. diabet*.mp.
12. 8 OR/11
Retinopathy 13. exp Eye Diseases/
14. exp Diabetic Retinopathy/
15. exp Retinal Neovascularization/
16. exp Macular Oedema/
17. retinopath*.mp.
18. maculopath*.mp.
19. background retinopathy.mp.
20. microaneurysm*.mp.
21. 13 OR/20
Prevalence 22. exp Epidemiology/
23. exp Prevalence/
24. exp Incidence/
25. exp Natural History/
26. frequenc*.mp.
27. epidemiolog*.mp.
28. prevalen*.mp.
29. inciden*.mp.
30. severity.mp.
31. 22 OR/30
Diagnostic tests 32. exp Photography/
33. exp Ophthalmoscopes/
34. exp Fluorescein Angiography/
35. exp Fundus Oculi/
36. exp Slit Lamp/
37. exp ophthalmoscopy/
38. Tomography, Optical Coherence/
39. Ultrasonography/
40. photo*.mp.
41. ophthalmoscop*. mp.
42. angiogram*. mp.
43. biomicroscopy.mp.
44. Optical coherence tomography.mp.
45. ultrasonograph*.mp.
46. fundus.mp.
47. Slim Lamp.mp.
48. fundoscop*.mp.
49. 32 OR/48
50. 7 AND 12 AND 21 AND 31 AND 49
51. limit 50 to yr=‘1995 -Current’
paediatric population required greater clarity in evidence 
base regarding the natural history and the burden of 
disease in this group.15–17
The aim of this systematic review is to estimate the 
prevalence of diabetic retinopathy in children and young 
people living with type 1 or type 2 diabetes, and to inves-
tigate potential sources of heterogeneity such as study 
sample characteristics (eg, age, diabetes type and dura-
tion, and glycaemic control), diagnostic methods and 
definition of diabetic retinopathy to inform screening 
strategies for the paediatric population.
MEthods/dEsIgn
The systematic review will be performed in accordance 
with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines, with 
this protocol written according to the PRISMA-P check-
list.18 The PRISMA-P checklist can be found as online 
supplementary additional file 1. The study has been regis-
tered on PROSPERO (CRD42017067178).
data sources and searches
The PubMed and EMBASE databases will be searched 
using the OvidSP platform. We will also manually review 
the references lists of identified articles. The search 
strategy (table 1) will include terms related to children or 
young people, diabetes, diabetic retinopathy, prevalence 
and diagnostic tests, and there will be no language restric-
tions. We will exclude studies published before January 
1995 as older studies are likely to have been conducted 
prior to the publication of the Diabetes Control and 
Complications Trial, which demonstrated decreased risk 
of diabetic retinopathy development or progression with 
tighter glycaemic control than that previously used in 
routine clinical practice, and may have led to significant 
changes in disease management and natural history.19
study eligibility criteria
We will include studies which report prevalence estimates 
of diabetic retinopathy among general populations of 
children and young people with diabetes mellitus, or 
studies from which the prevalence data may be derived 
(table 2). Eligible studies will be those which meet the 
following criteria.
 ► Participants
Individuals aged under 18 years living with types 1 
or 2 diabetes. Studies with median/mean age of the 
sample greater than 25 years or which include partici-
pants older than 30 years will be excluded.
 ► Disease measure
Report of the clinical examination method used to 
determine diabetic retinopathy status, and descrip-
tion of either retinal findings or grade of retinopathy 
using any grading systems which can be correlated to 
retinopathy features seen at the ophthalmic examina-
tion. This will allow comparison between the different 
grading systems used in screening programmes and 
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Table 2 Inclusion and exclusion criteria
Category Inclusion criteria Exclusion criteria
Population  ► Children and young people <18 years old included in 
the sample
 ► Children and young people from general population
 ►Median/mean sample age >25 years
 ► Participants >30 years old included
 ► Studies conducted in selected populations (eg, 
dialysis, post-transplanted)
Exposure  ► Type 1 or 2 diabetes  ► Other types of diabetes (eg, monogenic causes)
Outcome of 
interest
 ► Prevalence of diabetic retinopathy
 ► Test used to assess diabetic retinopathy reported
 ► Estimation of prevalence not possible with 
published data
Article  ► Published between 1 January 1995 and 31 October 
2016
 ► Duplicate reports (the most comprehensive 
version will be included)
clinical practice. Included grading systems will be 
displayed in a supplementary table along with the 
systematic review’s results.
Prevalence will be calculated using two cut-offs, any 
diabetic retinopathy and sight-threatening diabetic 
retinopathy, that is, grades of retinopathy that require 
prompt ophthalmic management to reduce the risk 
of irreversible visual impairment. Any diabetic retin-
opathy will be defined as background retinopathy or 
more severe disease. Sight-threatening diabetic retin-
opathy20 will be primarily defined as proliferative 
diabetic retinopathy or clinically significant maculop-
athy oedema, that is, retinal thickening at or within 
500 µm of the centre of the macula, and/or hard 
exudates at or within 500 µm of the centre of the 
macula, if associated with thickening of the adjacent 
retina, and/or a zone or zones of retinal thickening 
one disc area in size, any part of which is within one 
disc diameter of the centre of the macula.21 Addition-
ally, a secondary analysis using a more inclusive defi-
nition of sight-threatening diabetic retinopathy, that 
is, including severe non-proliferative diabetic retinop-
athy, will be conducted using the available data.
Conference abstracts with sufficient data on disease 
measure to determine eligibility will be included.
study selection
The search results will be extracted and managed using 
Microsoft Excel (Microsoft Corporation, Redmond, 
Washington, USA). Two independent investigators (MIB, 
ALS) will screen titles and abstracts, and then apply the 
eligibility criteria to full-text articles. Disagreements will 
be resolved by consensus following discussion. Arbitration 
by a third author (JSR) will be sought whenever necessary.
data extraction
Two investigators (MIB, ALS) will extract the data using 
a standardised form. The following data items will be 
extracted: first author, year of publication, design, country, 
year of study conduction, sample size, diabetes type, age at 
examination, diabetes duration, HbA1c, diagnostic test, 
diabetic retinopathy definition, number of any diabetic 
retinopathy cases, severity of diabetic retinopathy cases. If 
a study reports multiple prevalence estimates over time, 
the first prevalence estimate, that is, the estimate which is 
reported with baseline sample clinical characteristics, will 
be selected as the most informative measure. Characteris-
tics of children and young people with sight-threatening 
diabetic retinopathy will be also extracted. Authors will 
be contacted if data in the original publication is unclear.
Assessment of risk of bias in included studies
The risk of bias will be assessed with an adapted version 
of the tool developed by Hoy and colleagues22 (online 
Supplementary additional file 2). The sample will be 
considered representative of the target population (ie, 
‘general’ population) when all children and young 
people registered in a paediatric diabetes clinic, or 
living in a specified catchment area were potentially 
eligible for the study. Sources of information will be 
classified as appropriate where diabetic retinopathy 
status is assessed during the study (cross-sectional and 
prospective studies) or where prospective databases 
such as diabetic retinopathy screening registers are 
used.
data synthesis
A comprehensive table for summary of findings 
with narrative description of all eligible studies will 
be reported. However, only studies with a sample 
size equal or greater than 200 participants will be 
included in the meta-analysis. Small studies will be 
excluded to reduce variability due to imprecise esti-
mates. Pooled prevalence estimates of any diabetic 
retinopathy and of sight-threatening diabetic reti-
nopathy will be calculated by random effect model 
meta-analysis. Forest plots will be used to summarise 
individual and pooled estimates of the prevalence. 
Heterogeneity between studies will be assessed using 
the I2 statistic (values of 25%, 50% and 75% will be 
considered low, medium and high heterogeneity, 
respectively)23 and will be further explored through 
meta-regressions and subgroup analyses considering 
the following covariates: sample median/mean age, 
median/mean diabetes duration, type of diabetes, 
median/mean HbA1c, diagnostic test, and year of 
study conduction. All analyses will be performed with 
R statistical software V.3.3.2., and p values<0.05 will 
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be used as the threshold for statistical significance. 
Assessment of meta-bias(es) is not planned, as prelim-
inary searches of registered protocols have indicated 
that it is unlikely that eligible epidemiological studies 
are prospectively registered. As this systematic review 
is not investigating the evidence underpinning an 
intervention, confidence in the cumulative evidence 
cannot be calculated or assessed using the Grading 
of Recommendations Assessment, Development and 
Evaluation. The strength of the body of evidence will 
be examined through the assessment of risk of bias 
within included studies.
dIscussIon
Diabetic retinopathy is, in the early stages, an important 
marker of disease control, and in the later stages, a 
preventable cause of visual impairment and blindness. 
The burden of childhood diabetes is increasing, but there 
is a paucity of synthesised data on the prevalence and 
natural history of childhood diabetic retinopathy. This 
systematic review, using a clinically impactful taxonomy 
to calculate the prevalence of diabetic retinopathy, will 
provide currently unavailable prevalence estimates to 
inform screening policy and practice for children and 
young people living with diabetes.
Ethics and dissemination
Ethical approval is not needed as this study will use only 
anonymised published data. We will report the findings 
of this systematic review in a peer-reviewed journal, 
and share it with the relevant professionals including 
health service planners through our DECS collabora-
tive network.
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